WT1-specific TCR-transduced autologous T cells

WT1-specific TCR-transduced autologous T cells is an investigational adoptive cell therapy and gene therapy originally developed by University College London (UCL) in collaboration with the Cell and Gene Therapy Catapult and Cell Medica (later Kuur Therapeutics, acquired by Athenex) for the treatment of hematological malignancies, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). The therapy involves harvesting autologous peripheral blood T lymphocytes from the patient and genetically modifying them ex vivo using a retroviral vector to express a T-cell receptor (TCR) that specifically recognizes the Wilms' Tumor 1 (WT1) antigen presented in the context of HLA-A*02:01 molecules. To enhance the expression and specificity of the introduced WT1-targeting TCR, the retroviral vector also encodes small interfering RNAs (siRNAs) to silence endogenous TCR genes, thereby preventing TCR chain mispairing. The engineered T cells are then expanded and infused intravenously back into the patient. Clinical development has been evaluated in Phase I/II trials, demonstrating an acceptable safety profile and persistence of the engineered T cells in vivo.

Other names

autologous Cys1 WT1 TCR-transduced T cellsWT1 TCR-transduced autologous T cellsWT-1 TCR-transduced autologous T cellsWT 1 TCR-transduced autologous T cellsWT1-specific TCR-T cellsWT-1-specific TCR-T cellsWT 1-specific TCR-T cellsautologous WT1-specific TCR-T cells